Application Detail

Description of Medical Service

¹⁷⁷Lutetium PSMA i&t is a targeted radionuclide radiotherapy that enters the cancer cell via the PSMA receptor, which is overexpressed in prostate cancer, with expression increasing in metastatic and castrate resistant disease. Therapy is intended for patients with progressive metastatic castrate resistant prostate cancer after the disease has progressed despite chemotherapy. Screening with PSMA Positron Emission Tomography (PET) and FDG PET determines if the patient has an adequate level of PSMA ‘target’ at all sites of measurable disease such that they will be expected to derive significant benefit from the treatment.

Description of Medical Condition

Prostate cancer is one of the commonest cancers in Australia. Castrate-resistant prostate cancer is defined by disease progression despite androgen depletion therapy (reducing the amount of testosterone in the body) and may present as either a continuous rise in serum prostate-specific antigen levels (usually elevated in men with prostate cancer), the progression of pre-existing disease, and/or the appearance of new metastases.

Reason for Application

New MBS item

Medical Service Type

Therapeutic technology

Previous Application Number/s

1686

Associated Documentation

Application Form

Application Form (PDF 1920 KB)
Application Form (Word 1617 KB)

Consultation Survey

Consultation Survey (PDF 652 KB)
Consultation Survey (Word 27 KB)

PASC Consultation
Not applicable

MSAC Consultation
MSAC consultation input must be received by no later than Friday, 9 June 2023 for it to be considered by MSAC at its July 2023 meeting.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

Bypassing PASC

ESC

8-9 June 2023

MSAC

27-28 July 2023